相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat
Maximilian Schmitt et al.
DRUG METABOLISM AND DISPOSITION (2021)
The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents
Kyung Chan Park et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors
Xiang Nan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2
Dengshuai Wei et al.
BIOORGANIC CHEMISTRY (2019)
Selective Defluoroallylation of Trifluoromethylarenes
Chaosheng Luo et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Lais Osmani et al.
SEMINARS IN CANCER BIOLOGY (2018)
Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors
Linxiao Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
Jin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d] pyrimidine derivatives as dual PI3Kα/mTOR inhibitors
Fei Lei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors
Ju Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity
Alessandro A. Boezio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
Maria Leticia de Castro Barbosa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth
Xiaojuan Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Pankaj Bhargava et al.
CURRENT ONCOLOGY REPORTS (2011)
E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
Takayuki Nakagawa et al.
CANCER SCIENCE (2010)
Hepatocyte growth factor: a regenerative drug for acute hepatitis and liver cirrhosis
Shinya Mizuno et al.
REGENERATIVE MEDICINE (2007)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy
AM Levine et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of hypoxia-induced factors in tumor progression
P Vaupel
ONCOLOGIST (2004)
分享论文
